Sulwhasoo's 60th Anniversary: The Concentrated Ginseng Rejuvenating Cream Launched in 2000, Not 1966
- 11 minutes ago
- 8 min read
Sulwhasoo is marking sixty years of ginseng research this month, and the product the anniversary is attached to — the Concentrated Ginseng Rejuvenating Cream — went on sale in 2000. Both facts come from Amorepacific and both are true, because the sixty years belong to a research programme rather than to a jar. That distinction is the only part of this anniversary a young brand can actually copy, and it is worth more than it first looks.
Is the Sulwhasoo cream really sixty years old?
No, and the company has never said it is.
Amorepacific's corporate site describes the Concentrated Ginseng Rejuvenating line as "rooted in the essence of 60 years of ginseng science, first introduced in 1966 with the 'ABC Ginseng Cream'," and says it has "continuously evolved" through "generations of refinement." Sulwhasoo's own retail copy states that the cream has been a bestseller "for over 20 years since its launch in 2000," with roots in the 1966 product.
Read those two sentences together and the picture is clear. ABC Ginseng Cream and Concentrated Ginseng Rejuvenating Cream are different products with different names, thirty-four years apart. What runs continuously underneath them is not a stock-keeping unit. It is a line of research.
Notice the verbs the company chooses. "Rooted in." "First introduced." Never "continuously on sale." That is careful drafting, not an accident, and the care is instructive: Amorepacific is claiming ancestry, which is defensible, rather than continuity, which would not be.
The seam is the interesting part, and it is being skipped by everyone who reads the anniversary as sentiment.
What is Amorepacific actually celebrating with Beauty Crafted in Time?
On 2 September, Amorepacific announced a global campaign called Beauty Crafted in Time, built on the idea that accumulated time creates value.
The release sets out three programme types across four markets: a brand pop-up in China; a programme aimed at international media and key opinion leaders in Singapore; and art-collaboration exhibitions with global artists in the United States and Korea. A key opinion leader, in this context, is simply an industry term for a creator or specialist whose recommendation a category's buyers actually act on — the beauty industry's preferred phrase for what English-language marketing would call an influencer, though it usually implies more expertise and a smaller audience.
The campaign proposition is that time accumulates. Which it does — for the research, not for the cream.
What has Sulwhasoo actually launched in each market?
More than the release describes, and in registers that have very little to do with each other.
RetailBoss reported on 3 September that a century-old villa at Xintiandi No. 1 in Shanghai has been converted into the Sulwhasoo Ginseng Mansion, running from 29 August to 13 September, built around the research record rather than only around sampling and photogenic displays.
In Singapore, a pop-up takes the Level 1 Atrium of ION Orchard from 10 to 20 September, ten in the morning until ten at night, closed for a private event on 11 September between noon and half past six. That is a plainly public installation, with daily opening hours, in one of the busiest shopping centres in the region — and the corporate release describes Singapore only as a media and influencer programme. Nothing dishonest is happening there; a press release describes what the communications team is running, not the whole retail calendar. It is simply a reminder that the release is not the campaign.
And in Korea, on 4 September, the brand put out a holiday gift set built on the Rich texture of the cream, packed with a cleansing foam, the brand's first-step serum and a capsule serum, with a wrapping service drawn from Korean wrapping-cloth tradition offered on the main official e-commerce channels from 31 August to 27 September.
Why is a research narrative a better asset than an old product?
Because of which of the two a young brand can copy.
A villa exhibition in Shanghai, a shopping-mall atrium in Singapore and a holiday gift box in Seoul are three completely different sales registers. What carries all three is not the jar. It is a story about ginseng that Sulwhasoo has been telling, and funding, since before the current product existed — and which will outlast it.
Nobody can acquire a sixty-year-old product. That is what the word heritage means, and anniversaries built on it are, for everyone else, unreachable by construction. You either have one or you do not, and no amount of budget changes the answer this year.
An owned research narrative is a different asset with different economics.
It is portable. It survived the retirement of ABC Ginseng Cream and it survived every reformulation since, including the 2024 renewal that introduced the Ginseng Peptide complex alongside Ginsenomics. The products changed; the programme did not.
It starts when you start it, not when you founded the company. A brand incorporated four years ago cannot have an old product, but it can be four years into a research question — and each year it keeps going puts it somewhere its competitors cannot reach by spending, only by having started earlier.
And it is cumulative in a way product marketing is not. Each generation of the cream is evidence for the programme. Each hero SKU an indie brand launches is, at best, evidence for itself. A hero SKU is the single product a brand's growth actually rests on — the one that carries the reorders and gets the shelf. Replace it every cycle and you have a sequence of unrelated arguments; keep answering one question and you have a case.
What does it cost to keep a research narrative going?
More than most brands can carry, and it is worth being straight about why.
Most of the Korean exporters I work with have no such narrative, and the reason is not short-termism. It is that the retail calendar rewards the new item and nothing rewards the fifth year of an unglamorous line of enquiry.
Consider what a buyer's assortment review looks like from the brand's side. Once or twice a year, a retailer decides which products keep their shelf space and which are cut. Nothing in that meeting is improved by telling the buyer you have been studying the same ingredient for four years. What helps is a new item with a new claim and a launch plan. The same is true of a platform ranking and a short-form feed, which is why the pressure arrives from three directions at once and always points the same way.
So the cost of a research narrative falls up front, in the years when it is not yet an asset. It becomes valuable in precisely the period after most brands would have abandoned it. That is not a moral failing on anyone's part. It is a financing problem, and it should be argued as one internally rather than as a matter of taste.
Which claims in the anniversary release carry footnotes?
This is the second useful thing in the pack, and it takes about a minute to see.
Read the same material as a compliance document rather than a brand document and it tells you exactly which sentences the company expects to have to defend. The rule is simple: the claims that carry footnotes are the claims somebody could be made to prove.
"Sixty years of ginseng research" carries no footnote. Neither does "the world's first ginseng cosmetic" — which is Amorepacific asserting a superlative about itself, unattributed, in its own release and on its own site. I have found no independent verification of that superlative anywhere, which is not an accusation; it is the ordinary status of a heritage claim.
Every performance claim carries one.
Collagen restored by 38 per cent in 48 hours: in-vitro, collagen expression assay, and limited to the epidermis.
Micro-elasticity strengthened thirteen-fold: in-vitro, micro-elasticity indicator expression assay.
Number one in anti-ageing creams for eleven consecutive years: Beauté Research SAS, Korean prestige market, cumulative sales, 2015 to 2025 — and attaching to the Concentrated Ginseng collection, not to the single cream.
What does in-vitro mean, and why does the scoping matter?
In-vitro means the test was run outside a living body — on cultured cells or tissue models in a laboratory, rather than on volunteers using the product on their faces. It is a legitimate and widely used basis for a cosmetic claim. It is not the same thing as a clinical study, which uses human subjects under controlled conditions, and Sulwhasoo runs those too. The point is not that one has been substituted for the other. The point is that the release tells you which is which.
"Limited to the epidermis" is doing similar work. The epidermis is the outermost layer of skin. The qualifier restricts what the number is claiming to the layer actually measured, which forecloses the reading a casual reader would otherwise take — that something is being repaired throughout the skin.
Each of those qualifiers narrows the claim to exactly what the evidence supports, at the level of the individual sentence. That is what a claim file is: not a marketing document but a defensive one, assembled so that every assertion can be traced to the test that produced it. When a competitor complains to a regulator, or a market authority queries a label, the footnote is the whole of your answer.
The market-leadership footnote is scoped just as tightly. A prestige market, as a measurement category, is a defined price segment — it excludes mass-market and drugstore products entirely — so "number one" means number one within a boundary the research house drew, in one country, over a stated decade, for a collection rather than an item. Four constraints in one line.
Why did the leadership claim change shape in the English coverage?
Because scoping travels badly, and this is the part with a practical lesson attached.
Amorepacific's body copy says "cream" and puts "collection" in the footnote. From there the claim split as it moved. The Korean trade press carried the research house, the market and the decade. At least one English-language outlet reproduced the leadership claim as a bare fact about the single cream, with an asterisk it never resolved anywhere in the article — no research house, no market scope, no years.
Nobody invented anything. The elision was already latent in the original, and the second outlet simply inherited it and dropped the footnote that would have contained it.
If you export, assume this will happen to your claims too. The footnote is doing real work and it is the first thing lost in transmission — lost by distributors writing local copy, by retailers writing shelf talkers, and by press picking your release up in a language you do not read. Whatever you cannot afford to have detached from its qualifier should be in the sentence, not in the footnote.
What should a four-year-old K-beauty brand actually do?
Not "build a heritage." You cannot, and pretending otherwise produces the founder-story inflation the Korean export cohort already has too much of.
Take instead the two mechanics that are genuinely available.
Pick one question and keep answering it. One ingredient, or one mechanism, and a commitment to being the company that is still working on it after it stops being interesting to anyone else. Across products, not within one. That clock starts the day you start it, which is the whole advantage — the only reason Sulwhasoo can run this campaign is that somebody began in 1966 and nobody since has stopped.
Write your claims the way the footnotes are written. Scoped to the assay, scoped to the population, scoped to the layer, before a regulator or a competitor makes you do it. This costs nothing except the temptation to overstate, and it is the difference between a claim you can defend in a European or American review and a claim you quietly withdraw.
Sulwhasoo asserts the unfalsifiable part and scopes the falsifiable part to the sentence. A reviewer will only ever be reading the second half. The story buys the right to be considered; the footnotes are what you have to stand behind.
The anniversary is not the product's. It never was. That is the good news.
Comments